Global X S&P Biotech ETF (ASX:CURE)
Australia · Delayed Price · Currency is AUD 68.14
+0.14 (0.21%)
Jun 19, 2026, 3:43 PM AEST
57.73% (1Y)
| Assets | 43.18M |
| Expense Ratio | 0.45% |
| PE Ratio | n/a |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Frequency | n/a |
| Payout Ratio | n/a |
| 1-Year Return | +57.73% |
| Volume | 1,135 |
| Open | 68.06 |
| Previous Close | 68.00 |
| Day's Range | 67.92 - 68.31 |
| 52-Week Low | 42.49 |
| 52-Week High | 68.31 |
| Beta | 0.35 |
| Holdings | 10 |
| Inception Date | Nov 8, 2018 |
About CURE
The Global X S&P Biotech ETF, identified by its ticker CURE, endeavors to replicate the overall financial performance, encompassing both capital gains and dividends, of the S&P Biotechnology Select Industry Index, before any management fees and operational costs are deducted.
Asset Class Equity
Category Health Care
Region North America
Stock Exchange Australian Securities Exchange
Ticker Symbol CURE
Provider Global X
Index Tracked S&P Biotechnology Select Industry
Performance
CURE had a total return of 57.73% in the past year, including dividends. Since the fund's inception, the average annual return has been 7.64%.
Top Holdings
16.79% of assets| Name | Symbol | Weight |
|---|---|---|
| TG Therapeutics, Inc. | TGTX | 2.00% |
| Travere Therapeutics, Inc. | TVTX | 1.93% |
| Alkermes plc | ALKS | 1.89% |
| Twist Bioscience Corporation | TWST | 1.84% |
| Revolution Medicines, Inc. | RVMD | 1.75% |
| Exelixis, Inc. | EXEL | 1.50% |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1.50% |
| Krystal Biotech, Inc. | KRYS | 1.47% |
| Neurocrine Biosciences, Inc. | NBIX | 1.47% |
| Nuvalent, Inc. | NUVL | 1.44% |